logo-loader
Paradigm Biopharmaceuticals Ltd

Paradigm Biopharmaceuticals director acquires 140,000 shares valued at almost $170,000

Non-executive director Chris Fullerton participated in a $26.3 million entitlement offer and has also purchased shares on-market.

Coins in a jar
The company is making strong progress as it aims to commercialise injectable PPS

Paradigm Biopharmaceuticals Ltd (ASX:PAR) director Chris Fullerton has acquired 140,000 shares with a total value of almost $170,000 during May and June.

The non-executive director took part in the company’s rights issue in May, acquiring 104,500 shares.

He then purchased a further 10,000 shares in an on-market transaction on June 27, taking his overall holding to 970,000 shares held in direct and indirect interests.

READ: Paradigm Biopharmaceuticals CEO shows faith in company with $49,000 on-market purchase

Paradigm’s chief executive officer Paul Rennie has also demonstrated his confidence in the company with the on-market purchase of 35, 000 shares on June 28 valued at $49,000.

The company’s shares have been up more than 5% today to an intra-day high of $1.46.

READ: Paradigm Biopharmaceuticals Ltd fully funded as it advances iPPS development

Paradigm is focused on development and potential commercialisation of injectable PPS (iPPS) for three indications – Osteoarthritis (OA), Mucopolysaccharidosis (MPS) and Ross River virus (RRV).

It is on track to file pre-Investigational New Drug (IND) meeting packages for IND applications with US FDA in leading indications of OA and the Orphan indication for MPS.

Pending successful phase 3 trials, both OA and MPS have the potential to be significant commercial opportunities for Paradigm.

READ: Paradigm Biopharmaceuticals completes retail component of $26.3 million entitlement offer

The company is well-funded to progress this work with $78 million, which was topped up by a recent entitlement offer that raised $26.3 million, of which the retail component raised about $16.15 million with the remainder from the institutional component.

Quick facts: Paradigm Biopharmaceuticals Ltd

Price: 3.38 AUD

Market: ASX
Market Cap: $663.36 m
Follow

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Paradigm Biopharmaceuticals Ltd named herein, including the promotion by the Company of Paradigm Biopharmaceuticals Ltd in any Content on the...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Paradigm's drug developments sees growing market opportunities

Paul Rennie, chief executive for Paradigm Biopharmaceuticals, speaks with Proactive Investors.

on 17/8/17

2 min read